Ho, Ching Sze. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (leaves 142-160). / Abstracts in English and Chinese. / DECLARATION --- p.I / ACKNOWLEDGEMENTS --- p.II / ABSTRACT (ENGLISH VERSION) --- p.IV / ABSTRACT (CHINESE VERSION) --- p.VII / TABLE OF CONTENTS --- p.IX / LIST OF FUGURES --- p.XII / LIST OF TABLES --- p.XIII / LIST OF ABBREVIATIONS --- p.XV / Chapter CHAPTER 1: --- INTRODUCTION --- p.1 / Chapter 1.1 --- Biology of human papillomavirus --- p.2 / Chapter 1.1.1 --- History --- p.2 / Chapter 1.1.2 --- Classification --- p.3 / Chapter 1.1.3 --- Genome structure --- p.5 / Chapter 1.1.4 --- Life cycle --- p.9 / Chapter 1.2 --- Epidemiology of cervical cancer --- p.10 / Chapter 1.2.1 --- Cervical intraepithelial neoplasia and cervical cancer --- p.10 / Chapter 1.2.2 --- Spectrum of cervical neoplasia --- p.13 / Chapter 1.2.3 --- Incidence of cervical cancer --- p.15 / Chapter 1.2.4 --- Screening programme --- p.16 / Chapter 1.3 --- Risk factors for cervical cancer --- p.17 / Chapter 1.4 --- Oncogenic HPV infection --- p.20 / Chapter 1.4.1 --- Risk association --- p.21 / Chapter 1.4.2 --- Geographical distribution --- p.23 / Chapter 1.4.3 --- Age distribution --- p.24 / Chapter 1.4.4 --- Oncogenic property of HPV --- p.25 / Chapter 1.4.5 --- Sequence variation --- p.28 / Chapter 1.5 --- Prevention by vaccination --- p.30 / Chapter 1.6 --- Objectives --- p.31 / Chapter CHAPTER 2: --- MATERIALS AND METHODS --- p.33 / Chapter 2.1 --- HPV type and prevalence distribution --- p.34 / Chapter 2.1.1 --- Study population --- p.34 / Chapter 2.1.2 --- Specimen and epidemiological data collection --- p.34 / Chapter 2.1.3 --- DNA extraction --- p.35 / Chapter 2.1.4 --- PCR amplification of DNA --- p.36 / Chapter 2.1.4.1 --- PCR for Beta-globin --- p.36 / Chapter 2.1.4.2 --- PCR for HPV DNA --- p.37 / Chapter 2.1.5 --- HPV typing by reverse line-blot hybridization --- p.39 / Chapter 2.1.6 --- Statistical method --- p.40 / Chapter 2.2 --- HPV 52 SEQUENCE VARIATION --- p.43 / Chapter 2.2.1 --- Study population --- p.43 / Chapter 2.2.2 --- Specimen processing --- p.43 / Chapter 2.2.3 --- DNA extraction --- p.44 / Chapter 2.2.4 --- PCR amplification for sequencing --- p.45 / Chapter 2.2.4.1 --- Optimization of gene-specific PCR --- p.45 / Chapter 2.2.4.2 --- Validation of type-specificity of gene-specific PCR --- p.46 / Chapter 2.2.4.3 --- PCR for HPV52 E6 and E7 --- p.46 / Chapter 2.2.4.4 --- PCR for LI gene --- p.47 / Chapter 2.2.4.5 --- PCR for long control region (LCR) --- p.48 / Chapter 2.2.5 --- Purification of PCR products --- p.49 / Chapter 2.2.6 --- Sequencing --- p.50 / Chapter 2.2.6.1 --- Preparation of template --- p.50 / Chapter 2.2.6.2 --- Purification of template --- p.50 / Chapter 2.2.6.3 --- Sequencer and data analysis --- p.51 / Chapter 2.2.7 --- Statistical methods --- p.51 / Chapter CHAPTER 3: --- RESULTS --- p.54 / Chapter 3.1 --- HPV TYPE AND PREVALENCE DISTRIBUTION --- p.55 / Chapter 3.1.1 --- Study population --- p.55 / Chapter 3.1.2 --- HPV prevalence --- p.59 / Chapter 3.1.2.1 --- Prevalence for HPV infection --- p.59 / Chapter 3.1.2.2 --- HPV age-specific prevalence --- p.68 / Chapter 3.1.3 --- Epidemiological risk profile --- p.73 / Chapter 3.1.3.1 --- Age-adjusted analyses --- p.73 / Chapter 3.1.3.2 --- Multivariate analyses --- p.76 / Chapter 3.2 --- HPV52 SEQUENCE VARIATION --- p.79 / Chapter 3.2.1 --- Study population --- p.79 / Chapter 3.2.2 --- Sequence variability of HPV52 --- p.79 / Chapter 3.2.3 --- HPV52 --- p.82 / Chapter 3.2.3.1 --- Sequence variation of E6 ORF --- p.82 / Chapter 3.2.3.2. --- HPV52 E6 variants and risk for cervical neoplasia --- p.86 / Chapter 3.2.4 --- HPV52 E7 --- p.89 / Chapter 3.2.4.1 --- Sequence variation of E7 ORF --- p.89 / Chapter 3.2.4.2 --- HPV52 E7 variants and risk for cervical neoplasia --- p.93 / Chapter 3.2.5 --- HPV52 LI --- p.95 / Chapter 3.2.5.1 --- Sequence variation of LI ORF --- p.95 / Chapter 3.2.5.2 --- HPV52 LI variants and risk for cervical neoplasia --- p.100 / Chapter 3.2.6 --- HPV52 long control region (LCR) --- p.104 / Chapter 3.2.6.1 --- Sequence variation of LCR --- p.104 / Chapter 3.2.6.2 --- HPV52 LCR variants and risk for cervical neoplasia --- p.110 / Chapter CHAPTER 4: --- DISCUSSION --- p.113 / Chapter 4.1 --- HPV PREVALENCE AND TYPE DISTRIBUTION --- p.114 / Chapter 4.1.1 --- HPV prevalence --- p.114 / Chapter 4.1.2 --- Age-specific prevalence --- p.116 / Chapter 4.1.3 --- Epidemiological risk profile --- p.121 / Chapter 4.1.4 --- Conclusions --- p.126 / Chapter 4.2 --- HPV 52 SEQUENCE VARIATION --- p.127 / Chapter 4.2.1 --- Sequence variability of HPV52 --- p.127 / Chapter 4.2.2 --- Sequence variation of E6 gene --- p.129 / Chapter 4.2.3 --- Sequence variation of E7 gene --- p.132 / Chapter 4.2.4 --- Sequence variation of LI gene --- p.134 / Chapter 4.2.5 --- Sequence variation of LCR --- p.135 / Chapter 4.2.6 --- Conclusions --- p.139 / Chapter 4.3 --- FURTHER STUDIES --- p.140 / REFERENCES --- p.142 / APPENDIXES --- p.A

Thesis (Ph. D.)--Ohio State University, 2003. / Title from PDF t.p. (viewed on May 7, 2006). Includes bibliographical references (p. 297-304).

Introdução: Prurigo é uma terminologia de conotação sindrômica que tem o prurido como sintoma incondicional. O sinal é dermatológico, caracteristicamente manifestado por pápulas que se distribuem com relativa simetria pelo tegumento. Do ponto de vista clínico é uma condição de fácil suspeita, mas de difícil conclusão causal. Na Fundação Centro de Controle de Oncologia do Amazonas (FCECON), quadro de prurigo em pacientes oncológicos eram ocasionalmente identificados após início da radioterapia para o tratamento do tumor de base, contexto epidemiológico que não é classicamente relacionado ao prurigo. Objetivos: Descrever os aspectos clínicos, histopatológicos e imunoistoquímicos dos casos pósradioterapia. Métodos: estudo transversal, descritivo, de janeiro de 2006 a dezembro de 2012, com seleção de pacientes com CID de prurigo na FCECON. Serão descritas as características clínicas, histopatológicas e imunoistoquimicas dos casos com pesquisa de DNA viral do EBV, CMV e parvovírus B19. Resultados: Foram 35 mulheres e um homem, com idade média de 47 anos, sempre com queixa de prurido. A pelve sempre foi o campo irradiado com mediana de 28 dias para o surgimento dos sintomas. Foram 34 tumores ginecológicos com 31 casos de colo de útero. Ao todo ocorreram 13.339 lesões (média de 371), com 535 do grupo 1 (vesículas e urticas), 4.934 do grupo 2 (pápulas), 4.218 do grupo 3 (escoriações) e 3.652 do grupo 4 (residuais). Os membros inferiores foram acometidos em todos os casos e em 27 casos houve acometimento dos membros superiores. A histologia das 27 lâminas disponíveis identificou epiderme normal em cinco pacientes, atrofia em dois, espongiose em oito e alteração secundária ao prurido nas demais. Espongiose folicular e/ou espongiose do acrossiríngeo foram identificadas por nove ocasiões. Infiltrado perivascular superficial, profundo e intersticial composto por linfócitos e eosinófilos com distribuição perianexial foi o padrão mais encontrado na derme. O padrão do infiltrado foi de linfócitos T CD4 e ausência de linfócitos CD20 e linfócitos CD56. Não foi identificado DNA viral nas amostras examinadas. Discussão: O quadro de prurigo pós-radioterapia possui as mesmas características clínicoepidemiológicas e histológicas da síndrome EPPER. Histologicamente pode ser inclusa dentro das doenças inflamatórias eosinofílicas da pele, com padrão imunoistoquímico do infiltrado sugestivo de reação de hipersensibilidade mediada por linfócitos no padrão Th2. Como reação a picada de mosquitos foi o diagnóstico histológico de todos os casos, postula-se que o prurigo pós radioterapia, ou síndrome EPPER, seja reação imunológica precipitada pela exposição aos antígenos salivares do mosquito em um ambiente imune induzido pelo efeito abscopal secundário a irradiação pélvica. A natureza do estudo não permite confirmar esta conclusão, que deverá ser fruto de pesquisas futuras. Conclusões: O quadro de prurigo pós radioterapia esteve associado a irradiação da pelve, especialmente de tumores ginecológicos, com predomínio do câncer de colo de útero. Clinicamente semelhante a erupção pruriginosa, polimórfica, eosinofílica associada a radioditerapia (EPPER), pode ser classificado como prurigo agudo. As manifestações clínicas, histológicas e imunoistoquímicas são semelhantes ao quadro de hipersensibilidade a picada de mosquito do padrão celular, mediado por linfócitos Th2, sem evidencia de co-participação viral nos casos examinados / Introduction: Prurigo, a terminology used with a syndromic connotation, is characterized by pruritus, as an unconditional symptom, and papules usually distributed with relative symmetry by the integument. From the clinical point of view, it is a condition of easy suspicion, but of difficult causal conclusion. At the Fundação Centro de Controle de Oncologia do Amazonas (FCECON), prurigo was occasionally identified in cancer patients after radiation therapy for the treatment of the underlying tumor, an epidemiological context that is not classically related to prurigo. Objectives: To describe the clinical, histopathological and immunohistochemical aspects of post-radiotherapy prurigo. Methods: a cross-sectional, descriptive study, from January 2006 to December 2012, with the selection of patients with prurigo as classified by international classification of diseases in FCECON. The clinical, histopathological and immunohistochemical characteristics of the cases with viral DNA screening by RT-PCR EBV, CMV and parvovirus B19 is described. Results: There were 35 women and one man, with an average age of 47 years. Pruritus was always present. The pelvis was invariably the irradiated field with a median of 28 days for the onset of symptoms. There were 34 cases with gynecological tumors with 31 of the uterine cervix. A total of 13,339 lesions (mean of 371), with 535 of group 1 (vesicles and urticas), 4,934 of group 2 (papules), 4,218 of group 3 (excoriations) and 3,652 of group 4 (residual). The lower limbs were affected in all cases, and in 27 cases there was involvement of the upper limbs. The histology of the 27 available slides identified normal epidermis in five patients, atrophy in two, spongiosis in eight and alteration secondary to pruritus in the others. Follicular spongiosis or spongiosis of the acrosyringium were identified on nine occasions. A superficial, deep and interstitial perivascular infiltrate composed of lymphocytes and eosinophils with perianexial distribution was the most common pattern found in the dermis. The composition of the infiltrate was of CD3 CD4 T lymphocytes and absence of CD20 lymphocytes and CD56 lymphocytes. There were no viral DNA identified in the samples examined. Discussion: Postradiotherapy prurigo has the same clinical-epidemiological and histological characteristics of eosinophilic, polymorphic, pruritic associated with radiotherapy (EPPER) syndrome. Histologically it can be included within the inflammatory eosinophilic diseases of the skin, and the immunohistochemestry pattern of the infiltrate suggests a hypersensitivity reaction mediated by Th2 lymphocytes. Since a reaction to mosquito bites was the clinicopathological diagnosis of all cases, the authors postulate that post-radiation prurigo, or EPPER syndrome, is an immunological reaction precipitated by exposure to the mosquito\'s salivary antigens in an immune environment induced by the abscopal effect secondary to irradiation of the pelvis. The nature of the study does not allow this conclusion, which should be the result of future research. Conclusions: Post-radiation prurigo was associated with irradiation of the pelvis especially to treat gynecological tumors, with cancer of the cervix predominance. Clinically similar to EPPER syndrome, it can be classified as acute prurigo. Clinical, histological and immunohistochemical manifestations are similar to the hypersensitivity of Th2 lymphocytemediated mosquito bites, with no evidence of viral co-participation in the cases examined

No description available.

Au Yeung Chi Lam. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 204-221). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Tin-hung Ho. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1990. / Bibliography: leaves 137-151. / ACKNOWLEDGEMENT --- p.1 / CONTENT --- p.3 / ABBREVIATIONS --- p.7 / ABSTRACT --- p.8 / Chapter CHAPTER 1 --- INTRODUCTION --- p.10 / Chapter CHAPTER 2 --- LITERATURE REVIEW / Chapter 2.1 --- The cervix and cervical cancer --- p.12 / Chapter 2.2 --- Human papillomaviruses --- p.23 / Chapter 2.3 --- Culture of cancer cells --- p.36 / Chapter 2.4 --- Methods for the detection of HPV infection --- p.40 / Chapter CHAPTER 3 --- MATERIALS AND METHODS / Chapter 3.1 --- Characterization of cervical carcinoma cell lines / Chapter 3.1.1 --- Materials and solutions --- p.47 / Chapter 3.1.2 --- Establishment of cervical carcinoma cell lines --- p.50 / Chapter 3.1.3 --- Morphological studies of cervical carcinoma cells --- p.52 / Chapter 3.1.4 --- Examination of cervical carcinoma cells cultured on collagen gel --- p.54 / Chapter 3.1.5 --- Growth kinetics study --- p.55 / Chapter 3.1.6 --- Plating efficiency test --- p.56 / Chapter 3.1.7 --- Spheroid formation assay --- p.56 / Chapter 3.1.8 --- Chromosome number study --- p.57 / Chapter 3.2 --- Immunocytochemical studies / Chapter 3.2.1 --- Materials and solutions --- p.58 / Chapter 3.2.2 --- Immunocytochemical test for keratin --- p.59 / Chapter 3.2.3 --- Test for HPV capsid antigens --- p.60 / Chapter 3.3 --- Molecular studies of HPV in cervical carcinoma cells / Chapter 3.3.1 --- Materials and solutions --- p.62 / Chapter 3.3.2 --- Preparation of HPV DNA probes --- p.66 / Chapter 3.3.3 --- DNA extraction from the cervical carcinoma cells --- p.74 / Chapter 3.3.4 --- Detection of HPV DNA sequences by the use of hybridization techniques --- p.76 / Chapter 3.3.5 --- Copy number and physical state studies of HPV --- p.81 / Chapter 3.3.6 --- Study of the transcriptional activity of HPV DNA in cultured cervical carcinoma cells --- p.83 / Chapter CHAPTER 4 --- RESULTS / Chapter 4.1 --- Characterization of cervical carcinoma cell lines / Chapter 4.1.1 --- Morphological studies --- p.89 / Chapter 4.1.2 --- Examination of cervical carcinoma cells cultured on collagen gel --- p.90 / Chapter 4.1.3 --- Growth kinetics study --- p.93 / Chapter 4.1.4 --- Plating efficiency test --- p.94 / Chapter 4.1.5 --- Spheroid formation assay --- p.95 / Chapter 4.1.6 --- Chromosome number study --- p.98 / Chapter 4.2 --- Immunocytochemical studies / Chapter 4.2.1 --- Immunocytochemical test for keratin --- p.99 / Chapter 4.2.2 --- Test for HPV capsid antigen --- p.99 / Chapter 4.3 --- Molecular studies of HPV in cervical carcinoma cell lines / Chapter 4.3.1 --- Preparation of HPV DNA probes --- p.101 / Chapter 4.3.2 --- Detection of HPV DNA by the use of hybridization techniques --- p.102 / Chapter 4.3.3 --- Copy number and physical state studies --- p.105 / Chapter 4.3.4 --- Analysis of the transcriptional activity --- p.108 / Chapter CHAPTER 5 --- DISCUSSIONS / Chapter 5.1 --- Characterization of cervical carcinoma cell lines / Chapter 5.1.1 --- Morphological features of two cervical carcinoma cell lines --- p.110 / Chapter 5.1.2 --- Other characteristics of the cell lines --- p.112 / Chapter 5.2 --- Immunocytochemical studies / Chapter 5.2.1 --- Test for keratin antigens --- p.117 / Chapter 5.2.2 --- Test for HPV capsid antigens --- p.117 / Chapter 5.3 --- Molecular studies of HPV in cervical carcinoma cell lines / Chapter 5.3.1 --- Establishment of methods --- p.121 / Chapter 5.3.2 --- Detection of HPV DNA sequences by nucleic acid hybridizations --- p.123 / Chapter 5.3.3 --- Copy number and physical state studies --- p.128 / Chapter 5.3.4 --- Transcriptional analysis of HPV DNA in cervical carcinoma cell lines --- p.132 / CONCLUSION --- p.134 / REFERENCES --- p.137 / ILLUSTRATIONS --- p.152

Introdução: Prurigo é uma terminologia de conotação sindrômica que tem o prurido como sintoma incondicional. O sinal é dermatológico, caracteristicamente manifestado por pápulas que se distribuem com relativa simetria pelo tegumento. Do ponto de vista clínico é uma condição de fácil suspeita, mas de difícil conclusão causal. Na Fundação Centro de Controle de Oncologia do Amazonas (FCECON), quadro de prurigo em pacientes oncológicos eram ocasionalmente identificados após início da radioterapia para o tratamento do tumor de base, contexto epidemiológico que não é classicamente relacionado ao prurigo. Objetivos: Descrever os aspectos clínicos, histopatológicos e imunoistoquímicos dos casos pósradioterapia. Métodos: estudo transversal, descritivo, de janeiro de 2006 a dezembro de 2012, com seleção de pacientes com CID de prurigo na FCECON. Serão descritas as características clínicas, histopatológicas e imunoistoquimicas dos casos com pesquisa de DNA viral do EBV, CMV e parvovírus B19. Resultados: Foram 35 mulheres e um homem, com idade média de 47 anos, sempre com queixa de prurido. A pelve sempre foi o campo irradiado com mediana de 28 dias para o surgimento dos sintomas. Foram 34 tumores ginecológicos com 31 casos de colo de útero. Ao todo ocorreram 13.339 lesões (média de 371), com 535 do grupo 1 (vesículas e urticas), 4.934 do grupo 2 (pápulas), 4.218 do grupo 3 (escoriações) e 3.652 do grupo 4 (residuais). Os membros inferiores foram acometidos em todos os casos e em 27 casos houve acometimento dos membros superiores. A histologia das 27 lâminas disponíveis identificou epiderme normal em cinco pacientes, atrofia em dois, espongiose em oito e alteração secundária ao prurido nas demais. Espongiose folicular e/ou espongiose do acrossiríngeo foram identificadas por nove ocasiões. Infiltrado perivascular superficial, profundo e intersticial composto por linfócitos e eosinófilos com distribuição perianexial foi o padrão mais encontrado na derme. O padrão do infiltrado foi de linfócitos T CD4 e ausência de linfócitos CD20 e linfócitos CD56. Não foi identificado DNA viral nas amostras examinadas. Discussão: O quadro de prurigo pós-radioterapia possui as mesmas características clínicoepidemiológicas e histológicas da síndrome EPPER. Histologicamente pode ser inclusa dentro das doenças inflamatórias eosinofílicas da pele, com padrão imunoistoquímico do infiltrado sugestivo de reação de hipersensibilidade mediada por linfócitos no padrão Th2. Como reação a picada de mosquitos foi o diagnóstico histológico de todos os casos, postula-se que o prurigo pós radioterapia, ou síndrome EPPER, seja reação imunológica precipitada pela exposição aos antígenos salivares do mosquito em um ambiente imune induzido pelo efeito abscopal secundário a irradiação pélvica. A natureza do estudo não permite confirmar esta conclusão, que deverá ser fruto de pesquisas futuras. Conclusões: O quadro de prurigo pós radioterapia esteve associado a irradiação da pelve, especialmente de tumores ginecológicos, com predomínio do câncer de colo de útero. Clinicamente semelhante a erupção pruriginosa, polimórfica, eosinofílica associada a radioditerapia (EPPER), pode ser classificado como prurigo agudo. As manifestações clínicas, histológicas e imunoistoquímicas são semelhantes ao quadro de hipersensibilidade a picada de mosquito do padrão celular, mediado por linfócitos Th2, sem evidencia de co-participação viral nos casos examinados / Introduction: Prurigo, a terminology used with a syndromic connotation, is characterized by pruritus, as an unconditional symptom, and papules usually distributed with relative symmetry by the integument. From the clinical point of view, it is a condition of easy suspicion, but of difficult causal conclusion. At the Fundação Centro de Controle de Oncologia do Amazonas (FCECON), prurigo was occasionally identified in cancer patients after radiation therapy for the treatment of the underlying tumor, an epidemiological context that is not classically related to prurigo. Objectives: To describe the clinical, histopathological and immunohistochemical aspects of post-radiotherapy prurigo. Methods: a cross-sectional, descriptive study, from January 2006 to December 2012, with the selection of patients with prurigo as classified by international classification of diseases in FCECON. The clinical, histopathological and immunohistochemical characteristics of the cases with viral DNA screening by RT-PCR EBV, CMV and parvovirus B19 is described. Results: There were 35 women and one man, with an average age of 47 years. Pruritus was always present. The pelvis was invariably the irradiated field with a median of 28 days for the onset of symptoms. There were 34 cases with gynecological tumors with 31 of the uterine cervix. A total of 13,339 lesions (mean of 371), with 535 of group 1 (vesicles and urticas), 4,934 of group 2 (papules), 4,218 of group 3 (excoriations) and 3,652 of group 4 (residual). The lower limbs were affected in all cases, and in 27 cases there was involvement of the upper limbs. The histology of the 27 available slides identified normal epidermis in five patients, atrophy in two, spongiosis in eight and alteration secondary to pruritus in the others. Follicular spongiosis or spongiosis of the acrosyringium were identified on nine occasions. A superficial, deep and interstitial perivascular infiltrate composed of lymphocytes and eosinophils with perianexial distribution was the most common pattern found in the dermis. The composition of the infiltrate was of CD3 CD4 T lymphocytes and absence of CD20 lymphocytes and CD56 lymphocytes. There were no viral DNA identified in the samples examined. Discussion: Postradiotherapy prurigo has the same clinical-epidemiological and histological characteristics of eosinophilic, polymorphic, pruritic associated with radiotherapy (EPPER) syndrome. Histologically it can be included within the inflammatory eosinophilic diseases of the skin, and the immunohistochemestry pattern of the infiltrate suggests a hypersensitivity reaction mediated by Th2 lymphocytes. Since a reaction to mosquito bites was the clinicopathological diagnosis of all cases, the authors postulate that post-radiation prurigo, or EPPER syndrome, is an immunological reaction precipitated by exposure to the mosquito\'s salivary antigens in an immune environment induced by the abscopal effect secondary to irradiation of the pelvis. The nature of the study does not allow this conclusion, which should be the result of future research. Conclusions: Post-radiation prurigo was associated with irradiation of the pelvis especially to treat gynecological tumors, with cancer of the cervix predominance. Clinically similar to EPPER syndrome, it can be classified as acute prurigo. Clinical, histological and immunohistochemical manifestations are similar to the hypersensitivity of Th2 lymphocytemediated mosquito bites, with no evidence of viral co-participation in the cases examined

by Yam Hin Fai. / "June 1998." / Thesis (Ph.D.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (p. 118-151). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstract in Chinese.

Cervical cancer is the third leading cause of cancer death in women worldwide. Although cervical cancer is commonly infected with human papillomavirus (HPV), HPV infection alone is insufficient to induce malignant changes. Many characteristic genetic and epigenetic alterations have been identified in invasive cervical carcinomas but relatively little is known about the specific genetic and molecular alterations that allow pre-invasive epithelial cells to acquire the ability to progress to invasive squamous cell carcinomas. Recently, a family of small non-coding RNAs termed microRNAs (miRNAs) with specific inhibitory functions on target gene expression has been suggested to play an important role in the pathogenesis of human cancers including lung and breast cancer but remain undefined in cervical cancer. / Genome wide chromosomal copy number changes in cervical cancer by Agilent high-density array Comparative Genomic Hybridization demonstrated that only a very limited number of genomic imbalances have an impact on the miRNA profile in cervical cancer cells, although a high proportion of genomic loci containing miRNA genes exhibited DNA copy number alterations in other cancers. The impact of the genomic aberration on their mRNA expression was then confirmed by Aligent Whole Human Genome gene expression array. This suggests that the regulation of miRNA and mRNA expression may be different in cervical cancer. / In conclusion, our global miRNA profiling identified the common differentially expressed and genomic aberration independent miRNAs in cervical cancer. We further revealed the inhibition of hsa-miR-182 reduced tumor cell growth in vitro and in vivo through apoptosis and cell cycle mechanism. This provides new evidence that hsa-miR-182 may contribute to the pathogenesis of cervical cancer. / Keywords. MicroRNA, Cervical Cancer, Tumor Growth / To identify microRNA(s) associated with the tumorigenesis of cervical cancer, we firstly used the TaqMan MicroRNA Assays to survey and quantify a panel of 157 known human miRNAs in cervical cancer cell fines and micro-dissected normal cervical epithelium cells. We identified 2 microRNAs that were differentially up-regulated (fold change > 2, p < 0.05) and 9 differentially down-regulated (fold change > 2, p < 0.05) in cervical cancer cell lines comparing with normal cervical epithelium. Further investigation in tumor samples confirmed these two up-regulated miRNAs (hsa-miR-182 and -183 ) and 3 down-regulated miRNA (hsa-miR-145, 150, 195) from 4 investigated downregulated miRNAs (hsa-miR-145, 150, 195 and 328). / To investigate the biological function of those aberrantly expressed microRNAs, we chose one of the most aberrantly up-regulated microRNA ( hsa-miR-182, fold change > 10) for further investigation. Inhibition of hsa-miR-182 by antisense oligonucleotides inhibited HeLa cervical cancer cell growth in vitro and reduced tumor cell volume in vivo. Gene expression array analysis of HeLa cells with hsa-miR-182 knockdown and over-expression showed specific hsa-miR-182 targeting pathway in apoptosis and cell cycle. It indicated the roles of hsa-miR-182 in cervical cancer growth through apoptosis and cell cycle functions. / Tang, Tao. / Adviser: Richard K W Choy. / Source: Dissertation Abstracts International, Volume: 70-06, Section: B, page: 3446. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 155-169). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in English and Chinese. / School code: 1307.

Fung, Man See Joyce. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 111-120). / Abstracts in English and Chinese. / Table of Contents / Acknowledgements --- p.I / Abstract --- p.II / 論文摘要 --- p.VII / Table of Contents --- p.X / List of Figures --- p.XIV / List of Tables --- p.XVI / Abbreviations --- p.XVII / Chapter Chapter 1 - --- Introduction --- p.l / Chapter 1.1 --- Biology of HPV --- p.2 / Chapter 1.1.1 --- History --- p.2 / Chapter 1.1.2 --- Classification --- p.2 / Chapter 1.1.3 --- Genome structure --- p.3 / Chapter 1.2 --- HPV and cervical cancer --- p.8 / Chapter 1.2.1 --- Classification of cervical lesions --- p.8 / Chapter 1.2.2 --- Natural history of development of cervical cancer --- p.9 / Chapter 1.2.3 --- Risk factors --- p.11 / Chapter 1.3 --- Prevention of cervical cancer --- p.12 / Chapter 1.3.1 --- Vaccination --- p.12 / Chapter 1.3.2 --- Screening --- p.12 / Chapter 1.3.2.1 --- Pap test --- p.12 / Chapter 1.3.2.2 --- HPV DNA test --- p.13 / Chapter 1.3.2.3 --- Methylation pattern as a novel marker --- p.13 / Chapter 1.4 --- Biology of Methylation --- p.14 / Chapter 1.4.1 --- Definition --- p.14 / Chapter 1.4.2 --- Silencing effect --- p.18 / Chapter 1.4.3 --- Roles in normal development --- p.20 / Chapter 1.5 --- Methylation and human diseases --- p.20 / Chapter 1.5.1 --- Genetic diseases --- p.20 / Chapter 1.5.2 --- Cancers --- p.21 / Chapter 1.5.3 --- Methylation and oncogenic viruses --- p.23 / Chapter 1.5.4 --- Potential of methylation pattern as a novel biomarker of cancer --- p.24 / Chapter 1.5.5 --- Epigenetic therapy --- p.25 / Chapter 1.6 --- Methylation and HPV --- p.25 / Chapter 1.6.1 --- History --- p.25 / Chapter 1.6.2 --- Potential roles in transcription regulation of HPV --- p.26 / Chapter 1.6.3 --- Viral gene methylation --- p.27 / Chapter Chapter 2 - --- "Hypotheses, Objectives and Study Design" --- p.28 / Chapter 2.1 --- Hypotheses --- p.29 / Chapter 2.2 --- Objectives --- p.30 / Chapter 2.3 --- Study Design --- p.30 / Chapter Chapter 3 - --- Materials and Methods --- p.34 / Chapter 3.1 --- Work flow --- p.35 / Chapter 3.2 --- Study subjects --- p.37 / Chapter 3.2.1 --- Invasive cervical cancer group --- p.37 / Chapter 3.2.2 --- Low-grade group --- p.37 / Chapter 3.2.3 --- Cell lines --- p.38 / Chapter 3.3 --- DNA extraction --- p.38 / Chapter 3.4 --- HPV genotyping --- p.39 / Chapter 3.5 --- PCR of HPV16 LCR --- p.39 / Chapter 3.6 --- Sequencing of HPV 16 LCR --- p.42 / Chapter 3.6.1 --- Purification of PCR products --- p.42 / Chapter 3.6.2 --- Cycle sequencing reaction --- p.42 / Chapter 3.6.3 --- Purification of cycle sequencing products --- p.43 / Chapter 3.6.4 --- Sequencer and data analysis --- p.43 / Chapter 3.7 --- Bisulfite modification --- p.43 / Chapter 3.8 --- PCR of bisulfite modified LCR --- p.45 / Chapter 3.9 --- Cloning --- p.48 / Chapter 3.9.1 --- Ligation --- p.48 / Chapter 3.9.2 --- Transformation --- p.48 / Chapter 3.9.3 --- Colony PCR --- p.49 / Chapter 3.10 --- Sequencing of clones --- p.51 / Chapter 3.10.1 --- Purification of PCR products --- p.51 / Chapter 3.10.2 --- Cycle sequencing reaction --- p.51 / Chapter 3.10.3 --- Purification of cycle sequencing products --- p.52 / Chapter 3.10.4 --- Sequencer and data analysis --- p.52 / Chapter 3.11 --- Statistical methods --- p.52 / Chapter Chapter 4 - --- Results --- p.54 / Chapter 4.1 --- Sample selection --- p.55 / Chapter 4.2 --- HPV16 LCR PCR and sequencing --- p.57 / Chapter 4.3 --- Methylation patterns --- p.61 / Chapter 4.3.1 --- Cell lines --- p.61 / Chapter 4.3.2 --- Cancer group --- p.63 / Chapter 4.3.2.1 --- Overview --- p.63 / Chapter 4.3.2.2 --- Methylation pattern of the cancer samples --- p.66 / Chapter 4.3.2.3 --- Methylation pattern of the promoter region --- p.74 / Chapter 4.3.3 --- Low-grade group --- p.76 / Chapter 4.3.3.1 --- Overview --- p.76 / Chapter 4.3.3.2 --- Methylation pattern of the low-grade samples --- p.79 / Chapter 4.3.4 --- Comparison of the methylation patterns of the cancer samples and the low-grade samples --- p.84 / Chapter Chapter 5 - --- Discussion --- p.95 / Chapter 5.1 --- Sequence variations of HPV 16 LCR --- p.96 / Chapter 5.2 --- Methylation patterns of CaSki and SiHa cell lines --- p.98 / Chapter 5.3 --- Methylation pattern of the cancer samples --- p.99 / Chapter 5.4 --- Methylation pattern of the low-grade samples --- p.100 / Chapter 5.5 --- Comparison of methylation patterns of the cancer samples and the low-grade samples --- p.101 / Chapter 5.5.1 --- Promoter region in 3' LCR --- p.102 / Chapter 5.5.1.1 --- SP1 binding site --- p.102 / Chapter 5.5.1.2 --- E2BS3 and E2BS4 --- p.103 / Chapter 5.5.2 --- Silencer region --- p.104 / Chapter 5.5.3 --- Enhancer region in central LCR --- p.105 / Chapter 5.5.4 --- CpG sites within 5' LCR --- p.106 / Chapter 5.6 --- Role of methylation in HPV 16 --- p.107 / Chapter 5.7 --- Potential as novel biomarker --- p.108 / Chapter 5.8 --- Conclusions --- p.109 / References --- p.111 / Appendix A